

## Subject: RELPAX® 40mg Tablets - Recall

[Pfizer, Inc.](#) has issued a voluntary nationwide recall, to the consumer level, for two lots of RELPAX (eletriptan hydrobromide) 40mg tablets because these lots may not meet Pfizer’s in-house standard for potential bacterial contamination. RELPAX is indicated for the acute treatment of migraine with or without aura in adult patients.

Individuals who consume oral products contaminated with microorganisms are at risk of bacterial dissemination from the gut to the bloodstream potentially resulting in serious, life-threatening infections. In addition, there is risk of temporary gastrointestinal distress without serious infection. For the general population these risks are low; for certain vulnerable patient populations (such as patients with compromised immune systems, cystic fibrosis and chronic granulomatous disease) there may be the potential for serious adverse events including life-threatening infections. To date, Pfizer has not received any customer complaints or reports of adverse events related to this issue.

The affected lots (described below) were distributed nationwide to wholesalers, retailers, hospitals, and health care providers in the United States and Puerto Rico from June 2019 to July 2019.

Carton NDC	Lot	Exp Date	Strength	Configuration/Count
0049-2340-45	AR5407	2022 FEB	40mg	Carton containing 6 tablets (1 blister card x 6 tablets)
0049-2340-05	CD4565	2022 FEB	40mg	Carton containing 12 tablets (2 blister cards x 6 tablets)

Pfizer, Inc. is notifying its distributors and direct customers by certified letter and is arranging for return and replacement of all recalled products. In addition, pharmacies have been requested not to dispense any product subject to this recall and to notify any patients in possession of the recalled lots.

Injured workers that have products subject to this recall should return the product to their pharmacy or contact Stericycle Inc. at 877-225-9750 for instructions on how to return their product and obtain reimbursement for their cost.

For additional recall information, visit the [RELAPAX Recall Announcement](#).

### The Impact

First Script is working to identify injured workers who may have been affected and will be following up as necessary. For more information, please contact your Account Manager or Account Pharmacist.

If you have additional questions, please contact your Account Manager or Account Pharmacist.